Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy.
N. Engl. J. Med., Dec (2012)
Integration of immunotherapy into the management of advanced prostate cancer.
Urol. Oncol., 30(5 Suppl):S41-7 (2012 Sep-Oct)
Sexuality and intimacy after definitive treatment and subsequent androgen deprivation therapy for prostate cancer.
J. Clin. Oncol., Oct;30(30):3720-5 (2012)
Prostate cancer, Version 3.2012: featured updates to the NCCN guidelines.
J Natl Compr Canc Netw., Sep;10(9):1081-7 (2012)
Effects of androgen deprivation therapy and bisphosphonate treatment on bone in patients with metastatic castration resistant prostate cancer: results from the University of Washington rapid autopsy series.
J. Bone Miner. Res., Aug (2012)
Intermittent androgen suppression for rising PSA level after radiotherapy.
N. Engl. J. Med., Sep;367(10):895-903 (2012)
Improved overall survival trends of men with newly diagnosed M1 prostate cancer: a SWOG phase III trial experience (S8494, S8894 and S9346).
J. Urol., Oct;188(4):1164-9 (2012)
Re: interdisciplinary critique of sipuleucel-T as immunotherapy in castration-resistant prostate cancer.
J. Natl. Cancer Inst., Jul;104(14):1107-9; author reply 1109-12 (2012)
Detection of previously unidentified metastatic disease as a leading cause of screening failure in a phase III trial of zibotentan versus placebo in patients with nonmetastatic, castration resistant prostate cancer.
J. Urol., Jul;188(1):103-9 (2012)
Quantitative mathematical modeling of PSA dynamics of prostate cancer patients treated with intermittent androgen suppression.
J Mol Cell Biol., Jun;4(3):127-32 (2012)
Long-term dynamics of bone mineral density during intermittent androgen deprivation for men with nonmetastatic, hormone-sensitive prostate cancer.
J. Clin. Oncol., May;30(15):1864-70 (2012)
New and emerging agents for the treatment of castration-resistant prostate cancer.
Urol. Oncol., 29(6 Suppl):S1-8 (2011 Nov-Dec)
The role of sipuleucel-T in therapy for castration-resistant prostate cancer: a critical analysis of the literature.
Eur. Urol., Apr;61(4):639-47 (2012)
New treatment options for patients with metastatic castration-resistant prostate cancer.
Cancer Treat. Rev., Aug;38(5):340-5 (2012)
PROVENGE (Sipuleucel-T) in prostate cancer: the first FDA-approved therapeutic cancer vaccine.
Clin. Cancer Res., Jun;17(11):3520-6 (2011)
C11-acetate and F-18 FDG PET for men with prostate cancer bone metastases: relative findings and response to therapy.
Clin Nucl Med., Mar;36(3):192-8 (2011)
Sipuleucel-T immunotherapy for castration-resistant prostate cancer.
N. Engl. J. Med., Jul;363(5):411-22 (2010)
Nat Rev Drug Discov., Jul;9(7):513-4 (2010)
Duration of first off-treatment interval is prognostic for time to castration resistance and death in men with biochemical relapse of prostate cancer treated on a prospective trial of intermittent androgen deprivation.
J. Clin. Oncol., Jun;28(16):2668-73 (2010)
Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study.
Lancet., Apr;375(9724):1437-46 (2010)